Summary
Overview
Work History
Education
Skills
Publications
Activities
Timeline
Generic
Ramya Ravindranathan

Ramya Ravindranathan

Boston

Summary

Accomplished Scientist with 12+ years of expertise in DNA Damage Response (DDR) mechanisms, biomarker discovery, and translational cancer research. Proven ability to bridge academia and industry through sponsored research agreements, collaborative drug development, and preclinical validation.

  • Translational Leadership: Spearheaded projects from target discovery to biomarker-driven therapies for breast/ovarian cancers, with direct implications for clinical trial design.
  • Industry Collaboration: Managed cross-functional partnerships with biotech/pharma to advance DDR inhibitors (POLQ, USP1, PARG) from bench to IND-enabling studies.
  • High-Impact Innovation: Developed and published methodologies (e.g., ssDNA gap detection, BrDU-ssDNA assay for meiocytes) now utilized in diagnostic and therapeutic pipelines.
  • Team Builder: Led interdisciplinary teams (biologists, clinicians, computational scientists) to align research with unmet clinical needs.


Overview

12
12
years of professional experience

Work History

Research Scientist I

Dana Farber Cancer Center
01.2024 - Current
  • Center for DNA Damage and Repair and D’Andrea Lab
  • Led translational research projects utilizing clinical trial samples (e.g., tumor biopsies, blood derivatives) to validate DDR inhibitor mechanisms in ovarian/breast cancer cohorts.
  • Experience working with downstream assays in primary cells and patient-derived organoid models (e.g., DNA Fiber assay).
    • Collaborated with industry partners (Bristol Myers Squibb, Tango Therapeutics, EMD Serono,) to advance drug candidates into preclinical and clinical trials.
  • Collaborated with clinical teams to correlate biomarker data (e.g., ssDNA gaps) with therapeutic response in Phase I traits.

Senior Post doctoral fellow

Dana Farber Cancer Center
01.2022 - 12.2023
  • Center for DNA Damage and Repair and D’Andrea Lab
  • My goal has been to understand how DNA damage response pathway is regulated and how it can be exploited to develop effective targeted therapeutic measures for breast and ovarian cancer. Specifically, my work focusses on understanding the mechanism of toxicity and development of novel biomarkers of various DNA Damage Response (DDR) inhibitors response in cells, patient derived organoid models


Post-Doctoral Fellow

MGH Cancer Center
01.2020 - 12.2021
  • Elia Lab
  • My project focused on using proteomics and genetic approaches to understand DNA damage pathway regulated by ubiquitin-dependent signaling, specifically, DDR pathways that promote the stabilization and repair of stalled replication fork.


PhD Researcher

TU Dresden, Germany
01.2015 - 12.2019
  • Discovered a novel asynapsis pathway in oocyte quality control, published in Nucleic Acids Research.
  • Development of an assay for efficient ssDNA detection on chromosome axes using BrdU in meiocytes.
  • Mentored 5+ PhD students and Technicians.

Research Fellow

IISER Pune, India
01.2013 - 12.2014
  • Identified SUMOylation’s role in Drosophila immune signaling, with implications for cancer inflammation.

Education

Ph.D. -

TU Dresden
01.2019

M.Sc. -

SBP University
01.2013

B.Sc. -

P.S.G College of Arts of Arts and Science
01.2011

Skills

  • Molecular and cell biology
  • Developmental biology
  • Genetics
  • Cancer and DNA Damage
  • advanced Microscopy & Image analysis tools
  • Zeiss Zen
  • Adobe Photoshop
  • GraphPad
  • Fiji
  • Cell profiler
  • Molecular biology techniques
  • CRISPR Cas9
  • Cell and organ culture
  • Translational Research
  • DDR inhibitor development
  • Preclinical models
  • Drug screening
  • Technical Leadership
  • Proteomics
  • Genome instability assays
  • High-content imaging
  • Industry Collaboration
  • GLP practices
  • Biomarker validation
  • Project Management
  • Multidisciplinary team coordination
  • Grant writing
  • Data-to-decision pipelines

Publications


1.  Ramya R, Benjamin L , Alexandre ABAD, Nicholas WA, Sirisha M, , Huy N, Kalindi P, Geoffrey I S and Alan D D. Combined PARG and USP1 Inhibition Potentiates Tumor Cell Death in Breast and Ovarian Cancer Models (Manuscript in preparation).


2. Ramya R Ozge S, Alexandre ABAD, Sirisha M, Benjamin L, Huy N, Yuqing J, Joyce L , Bose K, Kalindi P, Geoffrey I S and Alan D D (2024). PARG inhibitor sensitivity correlates with accumulation of single stranded DNA gaps in preclinical models of ovarian cancer. (https://doi.org/10.1073/pnas.2413954121)


3. Alexandre ABAD, Ozge S, Ramya R, Sirisha M, David B M, Huy N, Yuqing J, Benjamin L Lisa M, Joyce Liu, Divya I, Jean-Bernard L, Geoffrey I S, Kalindi P, Alan D D (2024). Single-stranded DNA Gap Accumulation is a Functional Biomarker for USP1 Inhibitor Sensitivity. Cancer Research. doi: 10.1158/0008-5472.CAN-23-4007


4. Aleem S, Frantisek F, Jefferey PF, Albino B, Ramya R, Jia Zhou, Drew T. McDonald, Mohammed E. Albuhluli, Joseph A. Newman, Miaw-Sheue Tsai, Darin E. Jones, David C. Schriemer, Alan D. D'Andrea and John A. Tainer (2023) Novobiocin blocks nucleic acid binding to Polq and inhibits stimulation of its ATPase activity. Nucleic Acids Research, doi: 10.1093/nar/gkad727.


5. Ramya R, Kavya R,Frantzeskos P, Pedro A S, Attila T (2022). Chromosomal synapsis defects can trigger oocyte apoptosis without elevating numbers of persistent DNA breaks above wild-type levels. Nucleic Acids Research. https://doi.org/10.1093/nar/gkac355


6. Chandler M*, Selin E. Y*, Hanna C**, Ramya R**, Yodhara Wijesekara Hanthi, Juliana C. Levy, Vincenzo S, Detlev S, Alberto C , Vincenzo C, Andrew E. H. Elia (2023). RFWD3 Promotes ZRANB3 Recruitment to Regulate the Remodeling of Stalled Replication Forks . J Cell Biol . https://doi.org/10.1083/jcb.202106022


7. Anastasiia Bondarieva , Kavya R, Vladyslav T, H. B. D. Prasada R, Ramya R , Chrysoula Z , Friederike F, Ihsan D, Frantzeskos P, Daniel T, Alexander S, Ji-Feng F, Anna K, Masaru I, Dhananjaya SK, Ingo R, Neil H & Attila T (2020). Proline-rich protein PRR19 functions with cyclin-like CNTD1 to promote meiotic crossing over in mouse.Nature communications ;https://doi.org/10.1038/s41467-020-16885-3.


8. Frantzeskos P, Julie AJC, Erika T, Ramya R, Corin G, Ihsan D, Anastasiia B, Sarai VC, Marcello S, Alexender S, Petr J, Diana L, Fei J, Jiri F, Marco B, Bernard de M, Attila T (2019). ANKRD31 regulates spatiotemporal patterning of meiotic recombination initiation and ensures recombination between heterologous sex chromosomes in mice. Molecular Cell74, 1-17.


9. Friederike F, Ramya R, Ihsan D, Marcello S, Daniel T, Attila T (2016). Alignment of Homologous Chromosomes and Effective Repair of Programmed DNA Double-Strand Breaks during Mouse Meiosis Require the Minichromosome Maintenance Domain Containing 2 (MCMDC2) Protein. PloS Genet 12(10); e1006393; p1-26.


Mithila H, Bhagyashree K, Ramya R, Amarendranath S, Ritika G, Vijay BE, Harsha G, Girish SR (2015). SUMO-Enriched Proteome for Drosophila Innate Immune Response. G3 5(

Activities

  • Student Representative for DIPP-Dresden International PhD Program, 2015-2017
  • Active teaching member of ‘Science goes to school’, 2015-2017
  • Trained several medical and PhD students in biochemical and molecular biological techniques, 2017
  • Administrator and Cultural head of Indian Association Dresden, 2015-Present
  • Participated in 'Fame Lab Dresden 2019' as a science communicator, 2019

Timeline

Research Scientist I

Dana Farber Cancer Center
01.2024 - Current

Senior Post doctoral fellow

Dana Farber Cancer Center
01.2022 - 12.2023

Post-Doctoral Fellow

MGH Cancer Center
01.2020 - 12.2021

PhD Researcher

TU Dresden, Germany
01.2015 - 12.2019

Research Fellow

IISER Pune, India
01.2013 - 12.2014

M.Sc. -

SBP University

B.Sc. -

P.S.G College of Arts of Arts and Science

Ph.D. -

TU Dresden
Ramya Ravindranathan